查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1891248

生物製劑合約研究組織 (CRO) 市場：產業趨勢及全球預測（至 2035 年）－按生物製劑類型、業務規模、治療領域和地區劃分

Biologics Contract Research Organization Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Biologic, Scale of Operation, Therapeutic Area, and Geography
出版日期: | 出版商: Roots Analysis | 英文 235 Pages | 商品交期: 最快1-2個工作天內

價格

生物製劑合約研究組織 (CRO) 市場概況

預計今年全球生物製劑合約研究組織 (CRO) 市場規模將達到 360 億美元，並在預測期內以 13% 的複合年增長率 (CAGR) 高速增長，到 2035 年將達到 1260 億美元。

市場規模和機會分析基於以下參數進行細分：

生物製品類型

  • 疫苗
  • 細胞療法
  • 基因療法
  • 抗體
  • 重組蛋白/勝肽
  • 其他

業務規模

  • 臨床運營
  • 臨床前研究運營

治療領域

  • 腫瘤學
  • 心血管疾病
  • 發炎性疾病
  • 神經系統疾病
  • 其他

區域

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和北非
  • 世界其他地區

生物製劑合約研究與開發組織 (CRO) 市場 - 成長與趨勢

生物製劑是製藥業成長最快的領域之一。

這得益於該領域的快速發展，而這種發展又受到對高效、個人化藥物解決方案的需求的驅動。 生物製劑（包括單株抗體、基因療法和細胞療法）的需求不斷增長，這主要得益於它們在治療癌症、自體免疫疾病和神經系統疾病等慢性複雜疾病方面的成功應用。不斷擴充的生物製劑研發管線和日益提高的核准率進一步強化了這項需求。然而，生物製劑的開發和臨床評估是一個高度複雜且成本高昂的過程，需要專業知識和尖端的生物製程技術。因此，許多生物製劑公司選擇將藥物發現和臨床研究活動外包。

目前，生物製劑公司正在採用一種商業模式，即自行負責生物製劑的研發，同時將開發流程外包給外部服務提供者。生物製劑合約研究組織 (CRO) 產業正經歷著成長，這主要得益於對創新藥物和疾病研究的不斷深入。生物製劑的研發是勞力密集的，要求製藥公司具備先進的技術知識和專業技能，從而增加了藥品的整體成本。此外，嚴格的監管標準和審批流程可能會延遲藥物審批，並導致市場供應短缺。

為了簡化這些複雜的流程並應對相關挑戰，大型製藥公司正逐步將其生物製劑的研發業務外包給專業的合約研究組織 (CRO)。這種策略性外包方式使他們能夠利用外部專業知識，加速藥物發現和臨床試驗，並最終有效地將創新生物製劑推向市場。此外，人工智慧的整合有望加速藥物發現，簡化臨床試驗（例如，患者招募），並提高生產良率。生物加工自動化和分散式/虛擬臨床試驗的引入存在許多機遇，這將有助於降低成本並提高數據品質。因此，生物製劑 CRO 市場預計將穩定成長，以滿足生物製劑申辦者日益增長的研發需求。

生物製劑 CRO 市場 - 主要洞察

本報告深入分析了生物製劑 CRO 市場的現狀，並指出了該行業的潛在成長機會。 主要發現包括：

  • 目前，有160家公司聲稱具備為各類生物製品提供合約研究服務和臨床試驗支援的必要能力。
  • 約50%的業者僅提供臨床服務，而12%的CRO提供與生物製品臨床研究相關的所有服務。
生物製品合約研究組織市場-IMG2
  • 當前市場格局高度分散，既有成熟的公司，也有專業的服務供應商，它們提供廣泛的服務組合，以支持臨床前和臨床研究。
  • 據估計，大型製藥公司目前將其約45%的內部研發工作外包給CRO。
  • 超過三分之二的合約研究服務提供者位於北美和歐洲，其中大多數是中小企業。
  • 為了獲得競爭優勢，各公司正積極拓展現有能力，以進一步提升服務品質並適應不斷變化的行業標準。
生物製劑合約研究組織市場-IMG3
  • 目前，生物製劑開發公司正在評估和開發超過8000種候選產品，這為生物製劑CRO市場創造了機會。
  • 利害關係人對該領域的關注也反映在近期合作活動的增加。自2016年以來，業內人士已與申辦方和其他CRO簽署了多項協議。
  • 約 20% 的 CRO 提供臨床和臨床前生物製劑研究服務。
  • 為了因應日益增長的一站式服務需求，產業利害關係人正積極整合其生物製劑研究能力，主要透過併購和內部擴張的方式。
生物製劑合約研究組織市場-IMG4
  • 預計未來十年，該市場將以約 13% 的複合年增長率成長。這一成長機會很可能均勻分佈在各個治療領域、業務規模、生物製劑類型、最終用戶和地理區域。

生物製劑合約研究組織 (CRO) 市場 - 主要細分市場

預計臨床領域將佔生物製劑 CRO 市場最大的佔有率。

依業務規模劃分，全球生物製劑 CRO 市場分為三個部分：藥物發現、臨床前和臨床。目前，臨床規模的業務佔了大部分市場佔有率，其次是臨床前和藥物發現領域。

預計北美將佔生物製劑 CRO 市場最大的佔有率。

依地區劃分，市場分為北美、歐洲和亞太地區。預計北美將佔大部分市場佔有率 (50%)，其次是歐洲 (32%) 和亞太地區 (16%)。

生物製劑CRO市場代表性公司

  • 百康 (Biocon)
  • 科文斯 (Covance)
  • ICON
  • 美德佩斯 (Medpace)
  • 藥明康德 (Pharmaron)
  • PPD
  • PRA Health Sciences
  • Syneos Health
  • Vimta Labs
  • 藥明康德 (WuXi AppTec)

生物製劑CRO市場 - 研究範圍

  • 市場規模和機會分析：本報告對全球生物製劑合約研究與開發組織 (CRO) 市場進行了詳細分析，重點關注以下關鍵市場細分：[A] 生物製劑類型，[B] 業務規模，[C] 治療領域，以及 [D] 地區。
  • 市場概況：本報告基於以下相關參數對生物製劑服務市場進行全面評估：[A] 成立年份，[B] 公司規模，[C] 總部所在地，[D] 生產的生物製劑類型，[E] 業務規模，以及 [F] 提供的服務類型（包括臨床和非臨床服務）。
  • 公司簡介：提供生物製劑相關服務的合約研究組織 (CRO) 的詳細簡介，重點關注：[A] 公司概況，[B] 財務資訊（如有），[C] 服務組合，以及 [D] 近期發展和未來展望。
  • 基準分析：基於以下因素，對參與生物製劑合約研究與開發組織市場的公司進行全面的基準分析：[A] 公司在其同行群體中的能力，以獲得競爭優勢。
  • 合作夥伴關係與合作：基於多項參數，深入分析生物製劑CRO市場利益相關者簽署的合約協議，例如[A] 合作年份、[B] 合作類型、[C] 最活躍參與者（按簽署協議數量排名）、[D] 企業規模和[E] 地區。
  • 併購：基於相關參數，詳細分析該產業的併購活動：[A] 收購年份、[B] 合作類型、[C] 地區、[D] 最活躍的收購者、[E] 所有權變更矩陣、[F] 關鍵價值驅動因素和[G] 收購交易倍數。
  • 吸引力/競爭力矩陣：對收購目標進行全面分析，考慮自2016年以來已收購其他公司的企業的歷史活動，為其他行業參與者識別潛在收購目標提供參考。
  • SWOT 分析：分析可能影響生物製劑 CRO 市場發展的產業相關趨勢、機會與挑戰。包括哈維鮑爾分析，以評估每個 SWOT 參數對產業動態的相對影響。

目錄

第一章：前言

第二章：摘要整理

第三章：導論

第三章：導論

  • 章節概述
  • 生物製劑概述
  • CRO概述
  • CRO的發展歷程
  • CRO的分類
  • CRO提供的服務
  • 外包給CRO的優勢
  • 外包給CRO的風險

第四章 外包指南

  • 章節概述
  • 生物製劑研究外包
  • 外包模式
  • 選擇合適的外包方式模型
  • 選擇CRO合作夥伴
  • CRO在藥物研發過程中的作用
  • 結論

第五章：市場概況

  • 章節概述
  • 生物製劑CRO：市場概況
  • 臨床前生物製劑CRO
  • 臨床生物製劑CRO

第六章：公司簡介

  • 章節概述
  • 百康
  • 科文斯
  • ICON
  • Medpace
  • Pharmaron
  • PPD
  • PRA Health Sciences
  • Syneos 健康
  • Vimta Labs
  • WuXi AppTec

第七章：基準分析

  • 章節概述
  • 研究方法
  • 基準分析：同業群體

第八章：合作與夥伴關係

  • 章節概述
  • 合作模式
  • 生物製劑CRO：近期合作與夥伴關係

第九章：併購與收購

第十章：吸引力與競爭力矩陣

  • 章節概述
  • AC矩陣：概述
  • 分析與研究方法
  • AC矩陣：北美合約生產場景
  • AC矩陣：歐洲合約生產場景
  • AC矩陣：亞太及中東合約生產場景

第十一章：市場預測

  • 章節概述
  • 預測、研究方法及關鍵假設
  • 全球生物製劑CRO市場
  • 北美生物製劑CRO市場
  • 歐洲生物製劑CRO服務市場
  • 亞太地區生物製劑CRO服務市場
  • 拉丁美洲生物製劑CRO服務市場
  • 北美生物製劑CRO 服務市場

第十二章：SWOT 分析

第十三章：結論

第十四章：研究筆記

第十五章，附錄一：表格資料

第十六章，附錄二：公司與機構列表

Product Code: RA100260

Biologics Contract Research Organization Market: Overview

As per Roots Analysis, the global biologics contract research organization market valued at USD 36 billion in the current year and is anticipated to reach USD 126 billion by 2035, growing at a lucrative CAGR of 13% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Biologic

  • Vaccines
  • Cell Therapy
  • Gene Therapy
  • Antibodies
  • Recombinant Proteins / Peptides
  • Others

Scale of Operation

  • Clinical Operations
  • Preclinical Operations

Therapeutic Area

  • Oncological Disorders
  • Cardiovascular Disorders
  • Inflammatory Disorders
  • Neurological Disorders
  • Other Therapeutic Areas

Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and North Africa
  • Rest of the World

Biologics Contract Research Organization Market: Growth and Trends

Biologics are among the fastest expanding sectors within the pharmaceutical industry. This

can be linked to the swift advancement in this area, fueled by the demand for efficient and tailored pharmacological solutions. The increased need for biologics including monoclonal antibodies, gene therapies, and cell therapies is driven by their success in addressing chronic and complex ailments such as cancer, autoimmune diseases, and neurological disorders. This need is intensified by an expanding biologics pipeline and elevated approval rates. Nonetheless, the development and clinical evaluation of biologics is a very intricate and expensive procedure that requires specialized knowledge and cutting-edge bioprocessing technologies. Consequently, numerous biopharmaceutical firms are opting to delegate their drug discovery and clinical research activities.

At present, biopharmaceutical firms are adopting a business model wherein development processes are contracted to external service providers, while the firm itself oversees the R&D of these biologics. The biologics contract research organization sector is experiencing growth fueled by the rising research on innovative medications and illnesses. R&D of biologics is labor-intensive and pharmaceutical companies need significant technological knowledge and specialized expertise, which increases the overall expense of drugs. Moreover, strict regulatory standards and the approval process can delay the approval of drugs, resulting in a drug supply shortfall in the market.

To simplify these intricate processes and address related challenges, leading pharmaceutical companies are progressively delegating their biologics research and development efforts to specialized contract research organizations (CROs). This strategic outsourcing enables them to utilize external knowledge, speed up drug discovery and clinical trials, and ultimately launch innovative biologics to market more effectively. In addition, the integration of AI can speed up drug discovery, enhance clinical trials (such as patient recruitment), and boost manufacturing yields. The domain presents numerous opportunities in implementing automation for bioprocessing and decentralized / virtual clinical trials, which lower expenses and improve data quality. As a result, the biologics contract research organization market is expected to grow steadily to meet the increasing R&D needs of biopharmaceutical sponsors.

Biologics Contract Research Organization Market: Key Insights

The report delves into the current state of the biologics contract research organization market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Presently, 160 players claim to have the necessary capabilities to offer contract research services and clinical trial support for different types of biopharmaceutical products.
  • About 50% of all the players offer only clinical services; of these, 12% CROs provide all the services associated with clinical research of biologics.
Biologics Contract Research Organization Market - IMG2
  • The current market landscape is fragmented, featuring a mix of well-established players and specialty service providers, having extensive portfolios to support preclinical and clinical research.
  • It is estimated that big pharma players presently outsource close to 45% of their internal R&D operations to CROs.
  • More than two-thirds of the contract research service providers are based in North America and Europe; most of these players are small and mid-sized companies.
  • In order to gain a competitive edge, companies are actively expanding their existing capabilities in order to further augment their respective offerings and also comply with evolving industry benchmarks.
Biologics Contract Research Organization Market - IMG3
  • Over 8,000 product candidates are currently being evaluated / under development biologic drug developers, presenting opportunities in the biologics contract research organization market.
  • The growing interest of stakeholders in this field is also reflected in the increase in partnership activity in the recent past; since 2016, industry players have signed multiple deals with sponsor and / or other CROs.
  • Close to 20% of the CROs provide research services for biologics at the clinical and preclinical scales.
  • With the rising demand for one-stop shops, industry stakeholders are actively consolidating their capabilities related to biopharmaceutical research, mostly through mergers and acquisitions, and internal expansions.
Biologics Contract Research Organization Market - IMG4
  • The market is expected to grow at a CAGR of ~13% in the coming decade; the opportunity is likely to be well distributed across therapeutic areas, scales of operation, types of biologics, end users and geographical regions.

Biologics Contract Research Organization Market: Key Segments

Clinical Segment is Likely to Hold the Highest Share in the Biologics Contract Research Organization Market

In terms of the scale of operation, the global market for biologics contract research organization market is segmented into discovery, preclinical and clinical. Currently, majority share of the share is captured by clinical scale of operation, followed by preclinical and discovery segments.

North America is Anticipated to Capture the Maximum Biologics Contract Research Organization Market Share

In terms of geographical regions, the global market is segmented into North America, Europe and Asia-Pacific. Amongst these, North America is likely to capture majority (50%) of the market share, followed by Europe (32%) and Asia-Pacific (16%).

Example Players in the Biologics Contract Research Organization Market

  • Biocon
  • Covance
  • ICON
  • Medpace
  • Pharmaron
  • PPD
  • PRA Health Sciences
  • Syneos Health
  • Vimta Labs
  • WuXi AppTec

Biologics Contract Research Organization Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global biologics contract research organization market, focusing on key market segments, including [A] type of biologic, [B] scale of operation, [C] therapeutic area and [D] geography.
  • Market Landscape: A comprehensive evaluation of the biopharmaceutical services market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] types of biologics manufactured, [E] scale of operation and [F] types of services offered (including clinical services and preclinical services).
  • Company Profiles: In-depth profiles of CROs engaged in offering biopharmaceutical related services, focusing on [A] overview of the company, [B] financial information (if available), [C] service portfolio and [D] recent developments and an informed future outlook.
  • Benchmarking Analysis: A comprehensive benchmark analysis of players engaged in biologics contract research organization market based on the [A] capabilities of companies within a peer group with an aim to gain a competitive edge.
  • Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the biologics contract research organization market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] most active players (in terms of number of partnerships signed), [D] scale of operation and [E] geography.
  • Mergers and Acquisitions: An in-depth analysis of the mergers and acquisitions undertaken in this domain, based on relevant parameters, such as [A] year of acquisition, [B] type of collaboration, [C] geography, [D] most active acquirers, [E] ownership change matrix, [F] key value drivers and [G] acquisition deal multiples.
  • Attractiveness Competitiveness Matrix: A comprehensive acquisition target analysis, considering the historical trend of the activity of companies that have acquired other firms since 2016, and providing a means for other industry players to identify potential acquisition targets.
  • SWOT Analysis: An analysis of industry affiliated trends, opportunities and challenges, which are likely to impact the evolution of biologics contract research organization market; it includes a Harvey ball analysis, assessing the relative impact of each SWOT parameter on industry dynamics.

Key Questions Answered in this Report

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
    • 1.2.1. Research Assumptions
    • 1.2.2. Project Methodology
    • 1.2.3. Forecast Methodology
    • 1.2.4. Robust Quality Control
    • 1.2.5. Key Considerations
      • 1.2.5.1. Demographics
      • 1.2.5.2. Economic Factors
      • 1.2.5.3. Government Regulations
      • 1.2.5.4. Supply Chain
      • 1.2.5.5. COVID Impact / Related Factors
      • 1.2.5.6. Market Access
      • 1.2.5.7. Healthcare Policies
      • 1.2.5.8. Industry Consolidation
  • 1.3 Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3 Introduction

  • 3.1. Chapter Overview
  • 3.2. Overview of Biologics
    • 3.2.1. Types of Biologics
  • 3.3. Overview of Contract Research Organizations (CROs)
  • 3.4. Evolution of CROs
  • 3.5. Classification of CROs
  • 3.6. Services Offered by CROs
  • 3.7. Advantages of Outsourcing Operations to CROs
  • 3.8. Risks Associated with Outsourcing Operations to CROs

4. GUIDE TO OUTSOURCING

  • 4.1. Chapter Overview
  • 4.2. Outsourcing Biologics Research
  • 4.3. Models of Outsourcing
    • 4.3.1. Transactional Outsourcing Model
    • 4.3.2. Performance / Outcome-based Business Model
    • 4.3.3. Staff Augmentation Model
    • 4.3.4. Phase-Dependent Outsourcing Model
  • 4.4. Selecting an Appropriate Outsourcing Model
    • 4.4.1. Hybrid Approach
  • 4.5. Selecting a CRO Partner
    • 4.5.1. Key Considerations for Outsourcing Biologics-related Operations
  • 4.6. Role of CROs in the Drug Development Process
    • 4.6.1. Discovery and Preclinical Research
    • 4.6.2. Early Clinical Research
    • 4.6.3. Clinical Research and Laboratory Services
  • 4.7. Conclusion

5. MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Biopharmaceutical CROs: Overall Market Landscape
    • 5.2.1. Analysis by Year of Establishment, Company Size and Location of Headquarters
    • 5.2.2. Analysis by Scale of Operation
  • 5.3. Preclinical Biopharmaceutical CROs
    • 5.3.1. Analysis by Year of Establishment
    • 5.3.2. Analysis by Company Size
    • 5.3.3. Analysis by Location of Headquarters
    • 5.3.4. Analysis by Type of Biologic
    • 5.3.5. Analysis by Type of Services Offered
  • 5.4. Clinical Biopharmaceutical CROs
    • 5.4.1. Analysis by Year of Establishment
    • 5.4.2. Analysis by Company Size
    • 5.4.3. Analysis by Location of Headquarters
    • 5.4.4. Analysis by Type of Biologics
    • 5.4.5. Analysis by Type of Services Offered

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Biocon
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. Services Portfolio
    • 6.2.4. Future Outlook
  • 6.3. Covance
    • 6.3.1. Company Overview
    • 6.3.2. Service Portfolio
    • 6.3.3. Financial Information
    • 6.3.4. Future Outlook
  • 6.4. ICON
    • 6.4.1. Company Overview
    • 6.4.2. Financial Information
    • 6.4.3. Service Portfolio
    • 6.4.4. Future Outlook
  • 6.5. Medpace
    • 6.5.1. Company Overview
    • 6.5.2. Financial Information
    • 6.5.3. Service Portfolio
    • 6.5.4. Future Outlook
  • 6.6. Pharmaron
    • 6.6.1. Company Overview
    • 6.6.2. Services Portfolio
    • 6.6.3. Future Outlook
  • 6.7. PPD
    • 6.7.1. Company Overview
    • 6.7.2. Service Portfolio
    • 6.7.3. Financial Information
    • 6.7.4. Future Outlook
  • 6.8. PRA Health Sciences
    • 6.8.1. Company Overview
    • 6.8.2. Financial Information
    • 6.8.3. Service Portfolio
    • 6.8.4. Future Outlook
  • 6.9. Syneos Health
    • 6.9.1. Company Overview
    • 6.9.2. Financial Information
    • 6.9.3. Services Portfolio
    • 6.9.4. Future Outlook
  • 6.10. Vimta Labs
    • 6.10.1. Company Overview
    • 6.10.2. Services Portfolio
    • 6.10.3. Financial Information
    • 6.10.4. Future Outlook
  • 6.11. WuXi AppTec
    • 6.11.1. Company Overview
    • 6.11.2. Financial Information
    • 6.11.3. Service Portfolio
    • 6.11.4. Future Outlook

7. BENCHMARK ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Methodology
  • 7.3. Benchmark Analysis: Peer Groups
    • 7.3.1. Peer Group I
    • 7.3.2. Peer Group II
    • 7.3.3. Peer Group III
    • 7.3.4. Peer Group IV
    • 7.3.5. Peer Group V
    • 7.3.6. Peer Group VI
    • 7.3.7. Peer Group VII
    • 7.3.8. Peer Group VIII

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Biopharmaceutical CROs: Recent Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership Model
      • 8.3.2.1. Analysis by Year of Partnership and Type of Partnership Model
    • 8.3.3. Most Active Players: Analysis by Number of Partnerships
    • 8.3.4. Analysis by Scale of Operation
    • 8.3.5. Analysis by Geography
      • 8.3.5.1. Country-wise Analysis
      • 8.3.5.2. Intercontinental and Intracontinental Agreements

9. MERGERS AND ACQUISITIONS

  • 9.1. Chapter Overview
  • 9.2. Merger and Acquisition Models
  • 9.3. Biopharmaceutical CROs: Mergers and Acquisitions
    • 9.3.1. Analysis by Year of Acquisition
    • 9.3.2. Analysis by Type of Collaboration
    • 9.3.3. Analysis by Geography
      • 9.3.3.1. Continent-wise Distribution
      • 9.3.3.2. Country-wise Distribution
    • 9.3.4. Ownership Change Matrix
    • 9.3.5. Most Active Acquirers: Analysis by Number of Acquisitions
  • 9.4. Distribution by Key Value Drivers
    • 9.4.1. Analysis by Key Value Drivers
    • 9.4.2. Analysis by Key Value Drivers and Year of Acquisitions
  • 9.5. Valuation Analysis: Acquisition Deal Multiples

10. ATTRACTIVENESS COMPETATIVENESS MATRIX

  • 10.1. Chapter Overview
  • 10.2. AC Matrix: Overview
    • 10.2.1. Strong Business Segment
    • 10.2.2. Average Business Segment
    • 10.2.3. Weak Business Segment
  • 10.3. Analytical Methodology
  • 10.4. AC Matrix: Contract Manufacturing Scenario in North America
  • 10.5. AC Matrix: Contract Manufacturing Scenario in Europe
  • 10.6. AC Matrix: Contract Manufacturing Scenario in Asia Pacific and Middle East

11. MARKET FORECAST

  • 11.1. Chapter Overview
  • 11.2. Forecast Methodology and Key Assumptions
  • 11.3. Global Biopharmaceutical CROs Market
    • 11.3.1. Global Biopharmaceutical CROs Market: Distribution by Types of Biologics
    • 11.3.2. Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area
    • 11.3.3. Global Biopharmaceutical CROs Market: Distribution by Scale of Operation
    • 11.3.4. Global Biopharmaceutical CROs Market: Distribution by Geography
  • 11.4. Biopharmaceutical CROs Market in North America
    • 11.4.1. Biopharmaceutical CROs Market in North America: Distribution by Therapeutic Area
      • 11.4.1.1. Biopharmaceutical CROs Market for Oncological Disorders in North America, Till 2035
      • 11.4.1.2. Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, Till 2035
      • 11.4.1.3. Biopharmaceutical CROs Market for Inflammatory Disorders in North America, Till 2035
      • 11.4.1.4. Biopharmaceutical CROs Market for Neurological Disorders in North America, Till 2035
      • 11.4.1.5. Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, Till 2035
    • 11.4.2. Biopharmaceutical CROs Market in North America: Distribution by Scale of Operation
      • 11.4.2.1. Biopharmaceutical CROs Market for Preclinical Operations in North America, Till 2035
      • 11.4.2.2. Biopharmaceutical CROs Market for Clinical Operations in North America, Till 2035
  • 11.5. Biopharmaceutical CRO Services Market in Europe
    • 11.5.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Europe
      • 11.5.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Europe, Till 2035
      • 11.5.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Europe, Till 2035
      • 11.5.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Europe, Till 2035
      • 11.5.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Europe, Till 2035
      • 11.5.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Europe, Till 2035
    • 11.5.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Europe
      • 11.5.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Europe, Till 2035
      • 11.5.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Europe, Till 2035
  • 11.6. Biopharmaceutical CRO Services Market in Asia-Pacific
    • 11.6.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Asia-Pacific
      • 11.6.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Asia-Pacific, Till 2035
      • 11.6.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Asia-Pacific, Till 2035
      • 11.6.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Asia-Pacific, Till 2035
      • 11.6.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Asia-Pacific, Till 2035
      • 11.6.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Asia-Pacific, Till 2035
    • 11.6.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Asia-Pacific
      • 11.6.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Asia-Pacific, Till 2035
      • 11.6.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Asia-Pacific, Till 2035
  • 11.7. Biopharmaceutical CRO Services Market in Latin America
  • 11.8. Biopharmaceutical CRO Services Market in Middle East North America

12. SWOT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Strengths
  • 12.3. Weaknesses
  • 12.4. Opportunities
  • 12.5. Threats
  • 12.6. Comparison of SWOT Factors

13. CONCLUDING REMARKS

  • 13.1. Chapter Overview

14. SURVEY TRANSCRIPTS

15. APPENDIX I: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 4.1 Attributes of Transactional Outsourcing Based Business Model
  • Table 4.2 Comparison of Key Factors Considered by Biologic Developers for Selecting a CRO Partner: Harvey Ball Analysis
  • Table 5.1 Biopharmaceutical CROs: Information on Year of Establishment, Location of Headquarters, Company Size and Types of Biologics
  • Table 5.2 Biopharmaceutical Preclinical CROs: Information on Types of Services Offered
  • Table 5.3 Biopharmaceutical Clinical CROs: Information on Types of Services Offered
  • Table 6.1 Biocon: Company Overview
  • Table 6.2 Biocon: Future Outlook
  • Table 6.3 Covance: Company Overview
  • Table 6.4 Covance: Future Outlook
  • Table 6.5 ICON: Company Overview
  • Table 6.6 ICON: Future Outlook
  • Table 6.7 Medpace: Company Overview
  • Table 6.8 Medpace: Future Outlook
  • Table 6.9 Pharmaron: Company Overview
  • Table 6.10 Pharmaron: Future Outlook
  • Table 6.11 PPD: Company Overview
  • Table 6.12 PPD: Future Outlook
  • Table 6.13 PRA Health Sciences: Company Overview
  • Table 6.14 PRA Health Sciences: Future Outlook
  • Table 6.15 Syneos Health: Company Overview
  • Table 6.16 Syneos Health: Future Outlook
  • Table 6.17 VIMTA Labs: Company Overview
  • Table 6.18 WuXi App-Tec: Company Overview
  • Table 6.19 WuXi App Tec: Future Outlook
  • Table 7.1 Benchmark Analysis: Peer Groups
  • Table 8.1 Partnerships and Collaborations: List of Agreements, Since 2016
  • Table 9.1 Mergers and Acquisitions: List of Mergers / Acquisitions, Since 2016
  • Table 9.2 Mergers and Acquisitions: Information on Key Value Drivers, Since 2016
  • Table 9.3 Mergers and Acquisitions: Deal Multiples, Since 2016
  • Table 15.1 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
  • Table 15.2 Biopharmaceutical CROs: Distribution by Scale of Operation
  • Table 15.3 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
  • Table 15.4 Biopharmaceutical Preclinical CROs: Distribution by Company Size
  • Table 15.5 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
  • Table 15.6 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
  • Table 15.8 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
  • Table 15.9 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
  • Table 15.10 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types Services Offered
  • Table 15.11 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
  • Table 15.12 Biopharmaceutical Clinical CROs: Distribution by Company Size
  • Table 15.13 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
  • Table 15.14 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
  • Table 15.15 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
  • Table 15.16 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
  • Table 15.17 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
  • Table 15.18 Biocon: Annual Service Revenues, Since 2016 (INR Billion)
  • Table 15.19 Covance: Annual Service Revenues, Since 2016 (USD Billion)
  • Table 15.20 ICON: Annual Revenues, Since 2016 (USD Billion)
  • Table 15.21 Medpace: Annual Service Revenues, Since 2016 (USD Billion)
  • Table 15.22 PPD: Annual Service Revenues, Since 2016 (USD Billion)
  • Table 15.23 PRA Health Sciences: Annual Revenues, Since 2016 (USD Billion)
  • Table 15.24 Syneos: Annual Service Revenues, Since 2016 (USD Billion)
  • Table 15.25 Vimta Labs: Annual Service Revenues, Since 2016 (INR Billion)
  • Table 15.26 WuXi AppTec: Annual Service Revenues, Since 2016 (USD Billion)
  • Table 15.27 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 15.28 Partnerships and Collaborations: Distribution by Type of Partnership Model
  • Table 15.29 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership Model
  • Table 15.30 Most Active Players: Distribution by Number of Partnerships
  • Table 15.31 Partnerships and Collaborations: Distribution by Scale of Operation
  • Table 15.32 Partnerships and Collaborations: Distribution by Geography
  • Table 15.33 Partnerships and Collaborations: Country-Wise Distribution
  • Table 15.34 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 15.35 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition (Since 2016)
  • Table 15.36 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
  • Table 15.37 Mergers and Acquisitions: Distribution by Year and Type of Agreement
  • Table 15.38 Mergers and Acquisitions: Continent-wise Distribution
  • Table 15.39 Mergers and Acquisitions: Continent-wise Distribution
  • Table 15.40 Mergers and Acquisitions: Country-wise Distribution
  • Table 15.41 Mergers and Acquisitions: Ownership Change Matrix
  • Table 15.42 Mergers and Acquisitions: Key Value Drivers
  • Table 15.43 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
  • Table 15.44 Mergers and Acquisitions: Deal Multiples Based on Revenue
  • Table 15.45 Mergers and Acquisitions: Deal Multiples Based on Year of Experience
  • Table 15.46 Global Biopharmaceutical CROs Market: Distribution by Types of Biologics
  • Table 15.47 Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area
  • Table 15.48 Global Biopharmaceutical CROs Market: Distribution by Scale of Operation
  • Table 15.49 Global Biopharmaceutical CROs Market: Distribution by Geography
  • Table 15.50 Biopharmaceutical CROs Market in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.51 Biopharmaceutical CROs Market for Oncological Disorders in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.52 Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.53 Biopharmaceutical CROs Market for Inflammatory Disorders in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.54 Biopharmaceutical CROs Market for Neurological Disorders in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.55 Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.56 Biopharmaceutical CROs Market for Preclinical Operations in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.57 Biopharmaceutical CROs Market for Clinical Operations in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.58 Biopharmaceutical CROs Market in Europe, Till 2035 (USD Million)
  • Table 15.59 Biopharmaceutical CROs Market for Oncological Disorders in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.60 Biopharmaceutical CROs Market for Cardiovascular Disorders in Europe, Till 2035 (USD Million)
  • Table 15.61 Biopharmaceutical CROs Market for Inflammatory Disorders in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.62 Biopharmaceutical CROs Market for Neurological Disorders in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.63 Biopharmaceutical CROs Market for Other Therapeutic Areas in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.64 Biopharmaceutical CROs Market for Preclinical Operations in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.65 Biopharmaceutical CROs Market for Clinical Operations in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.66 Biopharmaceutical CROs Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.67 Biopharmaceutical CROs Market for Oncological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.68 Biopharmaceutical CROs Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.69 Biopharmaceutical CROs Market for Inflammatory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.70 Biopharmaceutical CROs Market for Neurological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.71 Biopharmaceutical CROs Market for Other Therapeutic Areas in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.72 Biopharmaceutical CROs Market for Preclinical Operations in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.73 Biopharmaceutical CROs Market for Clinical Operations in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.74 Biopharmaceutical CROs Market for Preclinical Operations in Latin America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.75 Biopharmaceutical CROs Market for Preclinical Operations in Middle East North Africa, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.76 Biopharmaceutical CROs Market: Conservative, Base and Optimistic Scenarios (USD Million)

List of Figures

  • Figure 3.1 Types of Biologics
  • Figure 3.2 Stages of the Drug Development Process
  • Figure 3.3 Commonly Offered Services by CROs
  • Figure 3.4 Advantages of Outsourcing Operations to CROs
  • Figure 3.5 Risks Associated with Outsourcing Operations to CROs
  • Figure 4.1 Guiding Models for Outsourcing
  • Figure 4.2 Key Characteristics of Transactional Outsourcing Model
  • Figure 4.3 Key Characteristics of Performance / Outcome based Business Model
  • Figure 4.4 Steps to Consider before Outsourcing
  • Figure 4.5 Key Considerations while Selecting a CRO Partner
  • Figure 4.6 Role of CROs in the Drug Development Process
  • Figure 5.1 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
  • Figure 5.2 Biopharmaceutical CROs: Distribution by Scale of Operation
  • Figure 5.3 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
  • Figure 5.4 Biopharmaceutical Preclinical CROs: Distribution by Company Size
  • Figure 5.5 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
  • Figure 5.6 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
  • Figure 5.7 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
  • Figure 5.8 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
  • Figure 5.9 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types of Services Offered
  • Figure 5.10 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
  • Figure 5.11 Biopharmaceutical Clinical CROs: Distribution by Company Size
  • Figure 5.12 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
  • Figure 5.13 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
  • Figure 5.14 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
  • Figure 5.15 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
  • Figure 5.16 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
  • Figure 6.1 Biocon: Annual Services Revenues, Since 2016 (INR Billion)
  • Figure 6.2 Biocon: Service Portfolio
  • Figure 6.3 Covance: Annual Services Revenues, Since 2016 (USD Billion)
  • Figure 6.4 Covance: Service Portfolio
  • Figure 6.5 ICON: Annual Revenues, Since 2016 (USD Billion)
  • Figure 6.6 ICON: Service Portfolio
  • Figure 6.7 Medpace: Annual Services Revenues, Since 2016 (USD Billion)
  • Figure 6.8 Medpace: Service Portfolio
  • Figure 6.9 Medpace: Regulatory Affair Capabilities
  • Figure 6.10 Pharmaron: Service Portfolio
  • Figure 6.11 PPD: Annual Services Revenues, Since 2016 (USD Billion)
  • Figure 6.12 PPD: Service Portfolio
  • Figure 6.13 PRA Health Sciences: Annual Revenues, Since 2016 (USD Billion)
  • Figure 6.14 PRA Health Sciences: Service Portfolio
  • Figure 6.15 Syneos Health: Annual Services Revenues, Since 2016 (USD Billion)
  • Figure 6.16 Syneos Health: Service Portfolio
  • Figure 6.17 Vimta Labs: Annual Service Revenues, Since 2016 (INR Billion)
  • Figure 6.18 Vimta Labs: Service Portfolio
  • Figure 6.19 WuXi App Tec: Annual Services Revenues, Since 2016 (USD Billion)
  • Figure 6.20 WuXi App Tec: Service Portfolio
  • Figure 7.1 Benchmark Analysis: Distribution by Company Size and Location of Headquarters
  • Figure 7.2 Benchmark Analysis: Peer Group I
  • Figure 7.3 Benchmark Analysis: Peer Group II
  • Figure 7.4 Benchmark Analysis: Peer Group III
  • Figure 7.5 Benchmark Analysis: Peer Group IV
  • Figure 7.6 Benchmark Analysis: Peer Group V
  • Figure 7.7 Benchmark Analysis: Peer Group VI
  • Figure 7.8 Benchmark Analysis: Peer Group VII
  • Figure 7.9 Benchmark Analysis: Peer Group VIII
  • Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership Model
  • Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership Model
  • Figure 8.4 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.5 Partnerships and Collaborations: Distribution by Scale of Operation
  • Figure 8.6 Partnerships and Collaborations: Distribution by Geography
  • Figure 8.7 Partnerships and Collaborations: Country-Wise Distribution
  • Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 9.1 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition (Since 2016)
  • Figure 9.2 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
  • Figure 9.3 Mergers and Acquisitions: Distribution by Year and Type of Merger / Acquisition
  • Figure 9.4 Mergers and Acquisitions: Continent-wise Distribution
  • Figure 9.5 Mergers and Acquisitions: Region-wise Distribution
  • Figure 9.6 Mergers and Acquisitions: Country-wise Distribution
  • Figure 9.7 Mergers and Acquisitions: Ownership Change Matrix
  • Figure 9.8 Mergers and Acquisitions: Key Value Drivers
  • Figure 9.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
  • Figure 9.10 Mergers and Acquisitions: Deal Multiples Based on Revenue
  • Figure 9.11 Mergers and Acquisitions: Deal Multiples Based on Year of Experience
  • Figure 10.1. AC Matrix: Pictorial Representation
  • Figure 10.2. AC Matrix: Positioning of Different Biologics in North America
  • Figure 10.3. AC Matrix: Positioning of Different Biologics in Europe
  • Figure 10.4. AC Matrix: Positioning of Different Biologics in Asia Pacific
  • Figure 11.1 Biopharmaceutical CROs: Market Forecast Methodology
  • Figure 11.2 Global Biopharmaceutical CROs Market, Till 2035
  • Figure 11.3 Global Biopharmaceutical CROs Market: Distribution by Types of Biologics
  • Figure 11.4 Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area
  • Figure 11.5 Global Biopharmaceutical CROs Market: Distribution by Scale of Operation
  • Figure 11.6 Global Biopharmaceutical CROs Market: Distribution by Geography
  • Figure 11.7 Biopharmaceutical CROs Market in North America, Till 2035 (USD Million)
  • Figure 11.8 Biopharmaceutical CROs Market for Oncological Disorders in North America, Till 2035 (USD Million)
  • Figure 11.9 Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, Till 2035 (USD Million)
  • Figure 11.10 Biopharmaceutical CROs Market for Inflammatory Disorders in North America, Till 2035 (USD Million)
  • Figure 11.11 Biopharmaceutical CROs Market for Neurological Disorders in North America, Till 2035 (USD Million)
  • Figure 11.12 Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, Till 2035 (USD Million)
  • Figure 11.13 Biopharmaceutical CROs Market for Preclinical Operations in North America, Till 2035 (USD Million)
  • Figure 11.14 Biopharmaceutical CROs Market for Clinical Operations in North America, Till 2035 (USD Million
  • Figure 11.15 Biopharmaceutical CROs Market in Europe, Till 2035 (USD Million)
  • Figure 11.16 Biopharmaceutical CROs Market for Oncological Disorders in Europe, Till 2035 (USD Million)
  • Figure 11.17 Biopharmaceutical CROs Market for Cardiovascular Disorders in Europe, Till 2035 (USD Million)
  • Figure 11.18 Biopharmaceutical CROs Market for Inflammatory Disorders in Europe, Till 2035 (USD Million)
  • Figure 11.19 Biopharmaceutical CROs Market for Neurological Disorders in Europe, Till 2035 (USD Million)
  • Figure 11.20 Biopharmaceutical CROs Market for Other Therapeutic Areas in Europe, Till 2035 (USD Million)
  • Figure 11.21 Biopharmaceutical CROs Market for Preclinical Operations in Europe, Till 2035 (USD Million)
  • Figure 11.22 Biopharmaceutical CROs Market for Clinical Operations in Europe, Till 2035 (USD Million)
  • Figure 11.23 Biopharmaceutical CROs Market in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.24 Biopharmaceutical CROs Market for Oncological Disorders in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.25 Biopharmaceutical CROs Market for Cardiovascular Disorders in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.26 Biopharmaceutical CROs Market for Inflammatory Disorders in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.27 Biopharmaceutical CROs Market for Neurological Disorders in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.28 Biopharmaceutical CROs Market for Other Therapeutic Areas in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.29 Biopharmaceutical CROs Market for Preclinical Operations in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.30 Biopharmaceutical CROs Market for Clinical Operations in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.31 Biopharmaceutical CROs Market in Latin America, Till 2035 (USD Million)
  • Figure 11.32 Biopharmaceutical CROs Market in Middle East North Africa, Till 2035 (USD Million)
  • Figure 11.33 Biopharmaceutical CROs Market: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.1 Biopharmaceutical CROs SWOT Analysis: Overview
  • Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 13.1 Concluding Remarks: Current Market Landscape for Preclinical Biopharmaceutical CROs
  • Figure 13.2 Concluding Remarks: Current Market Landscape for Clinical Biopharmaceutical CROs
  • Figure 13.3 Concluding Remarks: Recent Partnerships
  • Figure 13.4 Concluding Remarks: Mergers and Acquisitions
  • Figure 13.5 Concluding Remarks: Clinical Trial Analysis
  • Figure 13.6 Concluding Remarks: Market Sizing and Opportunity Analysis